Soleus Private Equity Fund I L.P. 13D and 13G filings for NeuroPace, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 3:36 pm Purchase |
2024-09-30 | 13G | NeuroPace, Inc. NPCE |
Soleus Private Equity Fund I L.P. | 2,433,168 8.200% |
400 (+0.02%) |
Filing |
| 2024-02-02 09:20 am Purchase |
2023-12-31 | 13G | NeuroPace, Inc. NPCE |
Soleus Private Equity Fund I L.P. | 2,432,768 9.300% |
63,765 (+2.69%) |
Filing |
| 2023-02-14 08:22 am Purchase |
2022-12-31 | 13G | NeuroPace, Inc. NPCE |
Soleus Private Equity Fund I L.P. | 2,369,003 9.500% |
60,000 (+2.60%) |
Filing |
| 2022-02-10 5:00 pm Purchase |
2021-12-31 | 13G | NeuroPace, Inc. NPCE |
Soleus Private Equity Fund I L.P. | 2,309,003 9.500% |
473,663 (+25.81%) |
Filing |
| 2021-11-01 5:16 pm Purchase |
2021-04-26 | 13G | NeuroPace, Inc. NPCE |
Soleus Private Equity Fund I L.P. | 1,835,340 7.600% |
1,835,340 (New Position) |
Filing |